Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).

German generics and consumer healthcare major STADA Arzneimittel and China’s Bio-Thera Solutions, a commercial-stage ...

US late-stage biotech Immunic, which is developing novel oral therapies for neurologic and gastrointestinal diseases, today ...

US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial ...

US mRNA specialist Moderna today reported fourth quarter 2025 earnings per share (EPS) of $2.11, $0.51 better than the analyst estimate of $2.62. Revenue for the quarter came in at $678 million versus ...

Danish CNS specialist Lundbeck has announced positive results from the multiple IV dosing part of PROCEED, an adaptive Phase IIb dose-finding and route of administration trial of bocunebart (Lu ...

Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.

At the 44th annual JP Morgan Healthcare conference, US biotech Insmed delivered one of the most closely watched updates in the respiratory space, detailing its clinical and commercial plans for 2026.

USA-based rare disease drug developer PTC Therapeutics saw its shares drop 5.2% to $67.05 after market close, when it announced that it has withdrawn the New Drug Application (NDA) resubmission for ...